MT Newswires
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
📊
AI Sentiment
Positive
7/10
as of 11-28-2025 12:38pm EST
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
| Founded: | 2002 | Country: | France |
| Employees: | N/A | City: | CHATILLON |
| Market Cap: | 464.0M | IPO Year: | N/A |
| Target Price: | $15.85 | AVG Volume (30 days): | 118.6K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.70 - $18.00 | Next Earning Date: | 10-28-2025 |
| Revenue: | $5,502,000 | Revenue Growth: | -56.04% |
| Revenue Growth (this year): | 1743.46% | Revenue Growth (next year): | 1045.66% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Medical Officer
Avg Cost/Share
$2.77
Shares
1,624
Total Value
$4,498.48
Owned After
101,529
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$2.88
Shares
6,496
Total Value
$18,708.48
Owned After
101,529
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mohideen Pharis | DBVT | Chief Medical Officer | Nov 21, 2025 | Sell | $2.77 | 1,624 | $4,498.48 | 101,529 | |
| Mohideen Pharis | DBVT | Chief Medical Officer | Nov 20, 2025 | Sell | $2.88 | 6,496 | $18,708.48 | 101,529 |
DBVT Breaking Stock News: Dive into DBVT Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
7/10
See how DBVT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "DBVT DBV Technologies S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.